Security key
71902K105
CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share (CERO)
CUSIP: 71902K105
Q4 2024 13F Holders as of 31 Dec 2024
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 13,323,470
- Total 13F value
- $956,030
- Share change
- +9,881,208
- SEC-reported price per share
- $0.06
- Number of holders
- 19
- Value change
- +$580,962
- Number of buys
- 15
- Number of sells
- 8
- Shares outstanding
- 5,169,697
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2024
Institutions
19
Top holders
10
CERO full security history
Ownership snapshot
Full 13F holder table
CERO THERAPEUTICS HOLDINGS, INC. SEC filings
CERO THERAPEUTICS HOLDINGS, INC. company facts
Broader feeds
Ownership snapshot
Top reported holders of CERO - CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
YK Bioventures Opportunit...
Disclosed value leader
YK Bioventures Opportunit...
Comparable rows
15/15
Latest evidence
11 Dec 2024
3/4/5
13D/G
13F
Lead comparable stake: 0.33%
13D/G row: YK Bioventures Opportunities GP I, LLC
Showing 1-6 of 15 holder rows.
Quick read
YK Bioventures Opportunities GP I, LLC leads the comparable SEC ownership view at 0.33%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens YK Bioventures Opportunities GP I, LLC's linked filing trail.
Comparable ownership
Top 5
YK Bioventures Opportunities GP I...
0.33%
ARCH Venture Management, LLC
28%
Avantax Planning Partners, Inc.
26%
GEODE CAPITAL MANAGEMENT, LLC
3%
Selkirk Management LLC
2.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| YK Bioventures Opportunities GP I, LLC |
3/4/5
13D/G
10%+ Owner
|
0.33%
from 13D/G
|
$780,310
13,005,169 shares
|
— | 11 Dec 2024 |
| ARCH Venture Management, LLC |
13F
Company
|
28%
|
$134,753
1,444,296 shares
|
— | 30 Sep 2024 |
| Avantax Planning Partners, Inc. |
13F
Company
|
26%
|
$126,993
1,361,130 shares
|
— | 30 Sep 2024 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
3%
|
$14,689
157,445 shares
|
— | 30 Sep 2024 |
| Selkirk Management LLC |
13F
Company
|
2.3%
|
$11,293
121,040 shares
|
— | 30 Sep 2024 |
| HRT FINANCIAL LP |
13F
Company
|
1.5%
|
$7,000
79,562 shares
|
— | 30 Sep 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
19
Shares
13,323,470
Rows available
19
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
17
Q4 2024 holders
19
Holder diff
2
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 value | Q4 2024 value | Value change | Value Chg % |
|---|